Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation

References

• Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129–1137. doi: 10.1002/cncr.21324
   PubMed Web of Science ®Google Scholar
• Larionova I, Rakina M, Ivanyuk E, et al. Radiotherapy resistance: identifying universal biomarkers for various human cancers. J Cancer Res Clin Oncol. 2022;148(5):1015–1031. doi: 10.1007/s00432-022-03923-4
   PubMed Web of Science ®Google Scholar
• Bibault J-E, Fumagalli I, Ferté C, et al. Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer Metast Rev. 2013;32(3):479–492. doi: 10.1007/s10555-013-9419-7
   PubMed Web of Science ®Google Scholar
• Slidesgo. Project Management Infographics. 2022 [cited 2022 Jul 6]. Available from: https://slidesgo.com/theme/project-management-infographics#search-Infographics&position-1&results-982.
   Google Scholar
• Slidesgo. Healthcare infographics. Human Icon And Test Tube Icon. 2022 [cited 2022 Jul 6]. Available from: https://slidesgo.com/theme/healthcare-infographics#search-healthcare&position-1&results-35.
   Google Scholar
• Wang J, Xu Z, Wang Z, et al. TGF-beta signaling in cancer radiotherapy. Cytokine. 2021;148:155709. doi: 10.1016/j.cyto.2021.155709
   PubMed Web of Science ®Google Scholar
• Tsai MS, Chen WC, Lu CH, et al. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling. Oral Oncol. 2019;91:47–55. doi: 10.1016/j.oraloncology.2019.02.027
   PubMed Web of Science ®Google Scholar
• Laube M, Kniess T, Pietzsch J. Development of antioxidant COX-2 inhibitors as Radioprotective agents for radiation therapy—A hypothesis-driven review. Antioxidants. 2016;5(2):14. doi: 10.3390/antiox5020014
   Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. doi: 10.1158/0008-5472.CAN-14-1258
   PubMed Web of Science ®Google Scholar
• Li JJ, Li R, Wang W, et al. IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer. Mol Oncol. 2018;12(5):602–610. doi: 10.1002/1878-0261.12182
   PubMed Web of Science ®Google Scholar
• Zhao L, Ma X, Liang M, et al. Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers. Cancer Imaging. 2019;19(1):49. doi: 10.1186/s40644-019-0234-4
   PubMedGoogle Scholar
• Bernsen MR, Kooiman K, Segbers M, et al. Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging. 2015;42(4):579–596. doi: 10.1007/s00259-014-2980-7
   PubMed Web of Science ®Google Scholar
• Sauter ER. Reliable biomarkers to identify New and recurrent cancer. Eur J Breast Health. 2017;13(4):162–167. doi: 10.5152/ejbh.2017.3635
   PubMed Web of Science ®Google Scholar
• Rinne SS, Orlova A, Tolmachev V. PET and SPECT imaging of the EGFR family (RTK class I) in Oncology. Int J Mol Sci. 2021;22(7):3663. doi: 10.3390/ijms22073663
   PubMed Web of Science ®Google Scholar
• Floberg JM, Wells SA, Ojala D, et al. Using 18F-DCFPyL prostate-specific membrane Antigen–directed positron emission tomography/Magnetic resonance imaging to define intraprostatic boosts for prostate stereotactic body radiation therapy. Adv Radiat Oncol. 2023;8(5):101241. doi: 10.1016/j.adro.2023.101241
   PubMedGoogle Scholar
• Kuo F, Histed S, Xu B, et al. Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Mol Pharm. Mol Pharmaceut. 2014;11(11):3996–4006. doi: 10.1021/mp500056d
   PubMed Web of Science ®Google Scholar
• Onal C, Erbay G, Oymak E, et al. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients. Radiother Oncol. 2023;184:109677. doi: 10.1016/j.radonc.2023.109677
   PubMed Web of Science ®Google Scholar
• Rose PG, Sommers RM, Reale FR, et al. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84(1):12–16.
   PubMed Web of Science ®Google Scholar
• Tan Y, Wang X, Ma K, et al. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study. Int J Hyperthermia. 2022;39(1):190–199. doi: 10.1080/02656736.2021.2024279
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim DY, Kim SH, et al. Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: a multi-institutional and case-matched control study of KROG 14-12. Radiother Oncol. 2015;116(2):202–208. doi: 10.1016/j.radonc.2015.07.049
   PubMed Web of Science ®Google Scholar
• Kim TH, Han S-S, Park S-J, et al. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):e743–8. doi: 10.1016/j.ijrobp.2010.10.011
   PubMed Web of Science ®Google Scholar
• Jensen JL, Maclean GD, Suresh MR, et al. Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management. Int J Biol Markers. 1991;6(1):1–6. doi: 10.1177/172460089100600101
   PubMedGoogle Scholar
• Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452–478. doi: 10.6004/jnccn.2020.0016
   PubMed Web of Science ®Google Scholar
• Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2021;11:11. doi: 10.3389/fphar.2020.632079
   Web of Science ®Google Scholar
• Stewart J, Sahgal A, Chan AKM, et al. Pattern of recurrence of glioblastoma versus grade 4 IDH-Mutant astrocytoma following chemoradiation: a retrospective matched-cohort analysis. Technol Cancer Res Treat. 2022;21:21. doi: 10.1177/15330338221109650
   Web of Science ®Google Scholar
• Wang Z, JIANG W, WANG Y, et al. MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Rep. 2015;3(4):543–548. doi: 10.3892/br.2015.462
   PubMedGoogle Scholar
• Wirth MP, Engelhardt FM. PSA recurrence after primary curative therapy — local or systemic? Urologe. 2005;44(9):997–1008. doi: 10.1007/s00120-005-0879-4
   Web of Science ®Google Scholar
• Giuliani M, Gui B, Valentini AL, et al. Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and. CA 125 levels. Minerva Obstet Gynecol. 2017;69(6):538–547. doi: 10.23736/S0026-4784.17.04062-X
   Google Scholar
• Xu Y, Yang Y, Li L, et al. The α-RECIST (RECIST 1.1 combined with alpha fetoprotein): a novel tool for identifying tumor response of conversion-radiotherapy for Unresectable Hepatocellular carcinoma before hepatectomy. Front Oncol. 2022;12:12. doi: 10.3389/fonc.2022.905260
   Web of Science ®Google Scholar
• Kozakiewicz B, Chadzynska M, Dmoch-Gajzlerska E, et al. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumor Biol. 2016;37(7):9367–9374. doi: 10.1007/s13277-016-4784-9
   PubMedGoogle Scholar
• Shintani T, Matsuo Y, Iizuka Y, et al. Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy. Anticancer Res. 2017;37(9):5161–5167.
   PubMed Web of Science ®Google Scholar
• Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(1):90–97. doi: 10.1016/S0360-3016(03)00524-8
   PubMed Web of Science ®Google Scholar
• Toulany M. Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives. Clin Transl Radiat Oncol. 2023;38:6–14. doi: 10.1016/j.ctro.2022.10.004
   PubMed Web of Science ®Google Scholar
• Mortezaee K, Parwaie W, Motevaseli E, et al. Targets for improving tumor response to radiotherapy. Int Immunopharmacol; 2019;76: 76.
   Web of Science ®Google Scholar
• Ho V, Chung L, Lim SH, et al. Prognostic impact of TP53 mutations and tumor mutational load in colorectal cancer. Gastrointestinal Disorders. 2022;4(3):165–179. doi: 10.3390/gidisord4030016
   Google Scholar
• Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery. 2017;7(1):86–101. doi: 10.1158/2159-8290.CD-16-0127
   PubMed Web of Science ®Google Scholar
• Brown JM. Radiation damage to tumor vasculature initiates a program that promotes tumor recurrences. Int J Radiat Oncol Biol Phys. 2020;108(3):734–744. doi: 10.1016/j.ijrobp.2020.05.028
   PubMed Web of Science ®Google Scholar
• Breen KJ, O’Neill A, Murphy L, et al. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. Prostate. 2017;77(12):1288–1300. doi: 10.1002/pros.23389
   PubMed Web of Science ®Google Scholar
• Katano A, Takahashi W, Yamashita H, et al. The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy. Sci Rep. 2017;7(1):17805.
   PubMedGoogle Scholar
• Zhao Y, Kang J-H, Yoo K-C, et al. K-RAS acts as a critical regulator of CD44 to promote the invasiveness and stemness of GBM in response to ionizing radiation. Int J Mol Sci. 2021;22(20):10923. doi: 10.3390/ijms222010923
   PubMed Web of Science ®Google Scholar
• Kamamoto D, Saga I, Ohara K, et al. Association between CD133, CD44, and nestin expression and prognostic factors in high-grade meningioma. World Neurosurg. 2019;124:E188–E196. doi: 10.1016/j.wneu.2018.12.067
   Web of Science ®Google Scholar
• Arnold CR, Mangesius J, Skvortsova II, et al. The role of cancer stem cells in radiation resistance. Front Oncol. 2020;10:164. doi: 10.3389/fonc.2020.00164
   PubMedGoogle Scholar
• Stancheva G, Goranova T, Laleva M, et al. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int. 2014;2014:1–9. doi: 10.1155/2014/654727
   Web of Science ®Google Scholar
• Alamilla-Presuel JC, Burgos-Molina AM, González-Vidal A, et al. Factors and molecular mechanisms of radiation resistance in cancer cells. Int J Radiat Biol. 2022;98(8):1301–1315. doi: 10.1080/09553002.2022.2047825
   PubMed Web of Science ®Google Scholar
• Skvortsov S, Debbage P, Cho WC, et al. Putative biomarkers and therapeutic targets associated with radiation resistance. Expert Rev Proteomics. 2014;11(2):207–214. doi: 10.1586/14789450.2014.893194
   PubMed Web of Science ®Google Scholar
• Golia D’Augè T, Cuccu I, Santangelo G, et al. Novel insights into molecular mechanisms of endometrial diseases. Biomolecules. 2023;13(3):499. doi: 10.3390/biom13030499
   PubMed Web of Science ®Google Scholar
• Cuccu I, D’Oria O, Sgamba L, et al. Role of genomic and molecular biology in the modulation of the treatment of endometrial cancer: narrative review and perspectives. Healthcare (Basel). 2023;11(4):571. doi: 10.3390/healthcare11040571
   PubMedGoogle Scholar
• Deichaite I, Hopper A, Krockenberger L, et al. Germline genetic biomarkers to stratify patients for personalized radiation treatment. J Transl Med. 2022;20(1):360. doi: 10.1186/s12967-022-03561-x
   PubMed Web of Science ®Google Scholar
• Rasmussen M, Sowter P, Gallon R, et al. Mismatch repair deficiency testing in lynch syndrome-associated urothelial tumors. Front Oncol. 2023;13:1147591. doi: 10.3389/fonc.2023.1147591
   PubMed Web of Science ®Google Scholar
• Wu Y, Song Y, Wang R, et al. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96. doi: 10.1186/s12943-023-01801-2
   PubMed Web of Science ®Google Scholar
• Kuchur OA, Kuzmina DO, Dukhinova MS, et al. The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development. Acta Naturae. 2021;13(3):65–76. doi: 10.32607/actanaturae.11247
   PubMed Web of Science ®Google Scholar
• Galeaz C, Totis C, Bisio A. Radiation resistance: a matter of Transcription factors. Front Oncol. 2021;11:662840. doi: 10.3389/fonc.2021.662840
   PubMed Web of Science ®Google Scholar
• Kumari N, Das A, Bhatt AN. Interleukin-6 confers radio-resistance by inducing Akt-mediated glycolysis and reducing mitochondrial damage in cells. J Biochem. 2020;167(3):303–314. doi: 10.1093/jb/mvz091
   PubMed Web of Science ®Google Scholar
• Jagasia S. Literature search. Philadelphia, PA: Web of Science; 2023.
   Google Scholar
• Deldar Abad Paskeh M, Asadi S, Zabolian A, et al. Targeting cancer stem cells by dietary agents: an important therapeutic strategy against Human malignancies. Int J Mol Sci. 2021;22(21):11669. doi: 10.3390/ijms222111669
   PubMed Web of Science ®Google Scholar
• Tsunekuni K, Konno M, Haraguchi N, et al. CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure. Sci Rep. 2019;9(1):14861. doi: 10.1038/s41598-019-50968-6
   PubMedGoogle Scholar
• Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958–1969. doi: 10.1158/2326-6066.CIR-19-0228
   PubMed Web of Science ®Google Scholar
• Acikgoz E, Tatar C, Oktem G. Triptolide inhibits CD133(+)/CD44(+) colon cancer stem cell growth and migration through triggering apoptosis and represses epithelial-mesenchymal transition via downregulating expressions of snail, slug, and twist. J Cell Biochem. 2020;121(5–6):3313–3324. doi: 10.1002/jcb.29602
   PubMed Web of Science ®Google Scholar
• Ning ST, Lee S-Y, Wei M-F, et al. Targeting colorectal cancer stem-like cells with anti-CD133 Antibody-Conjugated SN-38 Nanoparticles. ACS Appl Mater Interfaces. 2016;8(28):17793–17804. doi: 10.1021/acsami.6b04403
   PubMed Web of Science ®Google Scholar
• Colton M, Cheadle EJ, Honeychurch J, et al. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol. 2020;15(1):254. doi: 10.1186/s13014-020-01678-1
   PubMed Web of Science ®Google Scholar
• McIntosh C, Conroy L, Tjong MC, et al. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nature Med. 2021;27(6):999–1005. doi: 10.1038/s41591-021-01359-w
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang Q, Lam S, et al. A review on application of deep learning algorithms in external beam radiotherapy automated treatment planning. Front Oncol. 2020;10:580919. doi: 10.3389/fonc.2020.580919
   PubMed Web of Science ®Google Scholar
• Howard FM, Kochanny S, Koshy M, et al. Machine learning–guided adjuvant treatment of head and neck cancer. JAMA Netw Open. 2020;3(11):e2025881. doi: 10.1001/jamanetworkopen.2020.25881
   PubMed Web of Science ®Google Scholar
• Leiser D, Samanta S, Eley J, et al. Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer. PLoS One. 2021;16(11):e0258951. doi: 10.1371/journal.pone.0258951
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Ben-Josef E, Thomas DG, et al. Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 2015;5(1):10867. doi: 10.1038/srep10867
   PubMedGoogle Scholar
• Barker CA, Bishop AJ, Chang M, et al. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys. 2013;86(3):504–509. doi: 10.1016/j.ijrobp.2013.02.012
   PubMed Web of Science ®Google Scholar
• Van Nifterik KA, Van den Berg J, Slotman BJ, et al. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol. 2012;107(1):61–67. doi: 10.1007/s11060-011-0725-z
   PubMed Web of Science ®Google Scholar
• Krauze AV, Myrehaug SD, Chang MG, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor Valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92(5):986–992. doi: 10.1016/j.ijrobp.2015.04.038
   PubMed Web of Science ®Google Scholar
• Cai HM, Pang X, Dong D, et al. Molecular decision tree algorithms predict individual recurrence pattern for locally advanced nasopharyngeal carcinoma. J Cancer. 2019;10(15):3323–3332. doi: 10.7150/jca.29693
   PubMed Web of Science ®Google Scholar